EDAP TMS SA will present at the Piper Sandler Healthcare Conference in New York City on December 2nd, featuring a fireside discussion and investor meetings led by CEO Ryan Rhodes and CFO Ken Mobeck.

EDAP TMS SA will release its Q3 2025 financial results on November 6th, hosting a conference call and webcast with key executives to discuss the company's performance.

EDAP TMS SA received the 2025 Industry Award for Innovations in Endourological Instrumentation from the Endourological Society for its Focal One High-Intensity Focused Ultrasound (HIFU) platform, recognizing its pioneering work in robotic HIFU for prostate cancer treatment.

French Ministry of Health approved reimbursement for Focal One Robotic HIFU procedure for prostate cancer treatment, marking a significant commercial milestone for EDAP TMS SA and potentially expanding access to non-invasive prostate cancer therapy.

EDAP TMS SA announced positive final results from the Focal Ablation Versus Radical Prostatectomy (FARP) Study, a randomized controlled trial comparing ultrasound energy-based focal ablation and robotic prostatectomy for the treatment of localized prostate cancer. The study demonstrated that the rate of treatment failure in the Focal Ablation gro...